Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey.
暂无分享,去创建一个
D. Poplack | S. Zimm | J. Collins | D. O'neill | I. Kerr
[1] J. Ward,et al. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. , 1982, Cancer research.
[2] T. N. Campbell,et al. High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule. , 1982, Cancer treatment reports.
[3] R. Floyd,et al. Clearance of Continuously Infused 5-Fluorouracil in Adults Having Lung or Gastrointestinal Carcinoma with or without Hepatic Metastases , 1982, Drug intelligence & clinical pharmacy.
[4] R. Kaplan,et al. Neurotoxicity of antineoplastic drugs. , 1982, Seminars in oncology.
[5] R. Floyd,et al. Cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol, and oxypurinol during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation. , 1982, Cancer treatment reports.
[6] J. Posner,et al. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients , 1982, Cancer.
[7] S. Howell,et al. Modulation of 5‐fluorouracil toxicity by allopurinol in man , 1981, Cancer.
[8] M. Boyd,et al. A sensitive method for determination of 5-fluorouracil and 5-fluoro-2'-deoxyuridine in human plasma by high-pressure liquid chromatography. , 1980, Analytical biochemistry.
[9] R. Dedrick,et al. Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes , 1980, Clinical pharmacology and therapeutics.
[10] V. Vaitkevicius,et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. , 1980, Cancer research.
[11] J. Rosenfeld,et al. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. , 1978, British Journal of Cancer.
[12] A. Ommaya,et al. Chronic ventricular cerebrospinal fluid sampling, drug injections, and pressure monitoring using subcutaneous reservoirs in monkeys. , 1977, Neurosurgery.
[13] R. Diasio,et al. Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. , 1976, Cancer treatment reviews.
[14] H. Weiss,et al. Neurotoxicity of commonly used antineoplastic agents (first of two parts). , 1974, The New England journal of medicine.
[15] D. B. Tower,et al. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. , 1973, Cancer research.
[16] H. Koenig,et al. The acute cerebellar syndrome in 5-fluorouracil chemotherapy: a manifestation of fluoroacetate intoxication. , 1970, Neurology.
[17] D. Hutchison,et al. The physiologic disposition of 5‐fluorouracil and 5‐fluoro‐2′‐deoxyuridine in man , 1964, Clinical pharmacology and therapeutics.
[18] J. Byfield,et al. Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. , 1985, Cancer Research.
[19] R. Blasberg. Pharmacokinetics and Metastatic Brain Tumor Chemotherapy , 1980 .
[20] C. Heidelberger,et al. Studies on Fluorinated Pyrimidines XVI. Metabolism of 5-Fluorouracil-2-C14 and 5-Fluoro-2′-deoxyuridine-2-C14 in Cancer Patients , 1963 .